Engineering of extracellular vesicles for efficient intracellular delivery of multimodal therapeutics including genome editors.
Liang X. et al, (2025), Nat Commun, 16
uORF-targeting steric block antisense oligonucleotides do not reproducibly increase RNASEH1 expression
Ahlskog N. et al, (2025), Molecular Therapy - Nucleic Acids, 36, 102406 - 102406
Progress and prospects in antisense oligonucleotide-mediated exon skipping therapies for Duchenne muscular dystrophy.
Chwalenia K. et al, (2025), J Muscle Res Cell Motil
An extracellular vesicle delivery platform based on the PTTG1IP protein.
Martin Perez C. et al, (2024), Extracell Vesicle, 4
Long-term dystrophin restoration supports development of splice correction therapy for DMD patients with exon 2 duplications
Roberts TC., (2023), Molecular Therapy Methods and Clinical Development, 31
EV-mediated promotion of myogenic differentiation is dependent on dose, collection medium, and isolation method
Hanson B. et al, (2023), Molecular Therapy - Nucleic Acids, 33, 511 - 528
Therapeutic approaches for Duchenne muscular dystrophy.
Roberts TC. et al, (2023), Nat Rev Drug Discov
Investigating Eukaryotic Elongation Factor 2 Kinase/Eukaryotic Translation Elongation Factor 2 Pathway Regulation and Its Role in Protein Synthesis Impairment during Disuse-Induced Skeletal Muscle Atrophy.
Vilchinskaya N. et al, (2023), Am J Pathol, 193, 813 - 828
Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD.
Hanson B. et al, (2022), Mol Ther Nucleic Acids, 30, 379 - 397
Exon skipping induces uniform dystrophin rescue with dose-dependent restoration of serum miRNA biomarkers and muscle biophysical properties.
Chwalenia K. et al, (2022), Mol Ther Nucleic Acids, 29, 955 - 968
AR cooperates with SMAD4 to maintain skeletal muscle homeostasis.
Forouhan M. et al, (2022), Acta Neuropathol, 143, 713 - 731
Nuclear microRNA-466c regulates Vegfa expression in response to hypoxia
Laitinen P. et al, (2022), PLoS ONE, 17